MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer

Xiaoping Wu, Tianchi Liu, Ou Fang, Wenhua Dong, Fengjun Zhang, Lindsey Leach, Xiaohua Hu, Zewei Luo

Research output: Contribution to journalArticlepeer-review

32 Citations (Scopus)
179 Downloads (Pure)


MicroRNAs (miRNAs) have recently been recognized as targets for anti-metastatic therapy against cancer malignancy. Development of effective miRNA mediated therapies remains a challenge to both basic research and clinical practice. Here we presented the evidence for a miR-708-5p mediated replacement therapy against metastatic lung cancer. Expression of miR-708-5p was substantially reduced in metastatic lung cancer samples and cancer cell lines when compared to non-metastatic counterparts. Expression of the miRNA suppressed cell survival and metastasis in vitro through its direct target p21, and inhibited the PI3K/AKT pathway and stem cell-like characteristics of lung cancer cells. Systemic administration of this miRNA in a mouse model of NSCLC using polyethylenimine (PEI)-mediated delivery of unmodified miRNA mimics induced tumor specific apoptosis. It also effectively protected the tested animals from developing metastatic malignancy without causing any observed toxicity. The findings strongly support miR-708-5p as a novel and effective therapeutic agent against metastatic malignancy of non-small cell lung cancer.

Original languageEnglish
Pages (from-to)2417-32
Number of pages16
Issue number3
Early online date14 Dec 2015
Publication statusPublished - 19 Jan 2016


Dive into the research topics of 'MicroRNA-708-5p acts as a therapeutic agent against metastatic lung cancer'. Together they form a unique fingerprint.

Cite this